LONDON – Another day, another shake-up in the generics world, with Hikma Pharmaceuticals plc agreeing to pay $2.65 billion for Boehringer Ingelheim GmbH's U.S. generics business Roxane Laboratories Inc. Read More
Sanofi SA has pledged to invest up to $2.2 billion in a new collaboration with Regeneron Pharmaceuticals Inc. in which the longtime partners will jointly develop and commercialize the programmed cell death protein-1 (PD-1) inhibitor REGN-2810 and other new immuno-oncology antibodies. Read More
Merck & Co. Inc. turned to a small Israeli biotech, Ccam Biotherapeutics Ltd., to pad its immuno-oncology (I-O) pipeline with a next-generation monoclonal antibody (MAb) targeting the immune checkpoint protein known as carcinoembryonic antigen-related cell adhesion molecule 1, or CEACAM1. Read More
The robust health care sector along with an investor passion for immuno-oncology helped Nantkwest Inc. to its $207 million IPO, selling 8.3 million shares at $25 each, above the targeted $20 to $23 price range and 1.3 million more shares than planned. Read More
Two studies reported new links between the gut and the brain, describing new interrelationships among early life stress, depression and the microbiome. Read More
The answer to reducing the cost and time of developing drugs for unmet needs seems pretty obvious – a better understanding of the disease, the patient and the molecule being developed. Read More
Cara Therapeutics Inc., of Shelton, Conn., has commenced an underwritten public offering of shares of its common stock of up to $65 million, granting the underwriters a 30-day option to purchase an additional 15 percent of the number of shares sold on the same terms and conditions. Stifel and Piper Jaffray & Co. are acting as joint book-running managers for the proposed offering. Read More
Georg-August-University Göttingen (UMG) and MRC Technology (MRCT), of London, signed an exclusive license to develop a therapy for neurodegenerative diseases based on antibody-targeting amyloid beta peptides. Read More
United Therapeutics Corp., of Silver Spring, Md., reported second quarter revenues of $347.2 million for net income of $99.2 million, or $1.91 per diluted share. Read More
Fibrogen Inc., of San Francisco, said the FDA cleared the firm to proceed with a phase II study of FG-3019, a fully human monoclonal antibody designed to inhibit the activity of connective tissue growth factor, in patients with Duchenne muscuar dystrophy. Read More
